These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1198 related items for PubMed ID: 27012908

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment.
    Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H.
    J Nephrol; 2017 Feb; 30(1):127-134. PubMed ID: 26995002
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.
    Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C.
    Kidney Int; 2015 May; 87(5):1061-73. PubMed ID: 25651368
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
    Menne J, Delmas Y, Fakhouri F, Licht C, Lommelé Å, Minetti EE, Provôt F, Rondeau E, Sheerin NS, Wang J, Weekers LE, Greenbaum LA.
    BMC Nephrol; 2019 Apr 10; 20(1):125. PubMed ID: 30971227
    [Abstract] [Full Text] [Related]

  • 9. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Kato H, Miyakawa Y, Hidaka Y, Inoue N, Ito S, Kagami S, Kaname S, Matsumoto M, Mizuno M, Matsuda T, Shimono A, Maruyama S, Fujimura Y, Nangaku M, Okada H.
    Clin Exp Nephrol; 2019 Jan 10; 23(1):65-75. PubMed ID: 29959568
    [Abstract] [Full Text] [Related]

  • 10. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
    Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V.
    Am J Kidney Dis; 2014 Jan 10; 63(1):40-8. PubMed ID: 24021908
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
    Gediz F, Payzin BK, Ecemis S, Güler N, Yilmaz AF, Topcugil F, Berdeli A.
    Transfus Apher Sci; 2016 Dec 10; 55(3):357-362. PubMed ID: 27742267
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.
    Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G.
    J Thromb Haemost; 2014 Sep 10; 12(9):1440-8. PubMed ID: 24853860
    [Abstract] [Full Text] [Related]

  • 16. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
    Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA, 312 Study Group.
    Kidney Int; 2021 Jul 10; 100(1):225-237. PubMed ID: 33307104
    [Abstract] [Full Text] [Related]

  • 17. Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis.
    Legendre CM, Campistol JM, Feldkamp T, Remuzzi G, Kincaid JF, Lommelé Å, Wang J, Weekers LE, Sheerin NS.
    Transpl Int; 2017 Dec 10; 30(12):1275-1283. PubMed ID: 28801959
    [Abstract] [Full Text] [Related]

  • 18. Interventions for atypical haemolytic uraemic syndrome.
    Pugh D, O'Sullivan ED, Duthie FA, Masson P, Kavanagh D.
    Cochrane Database Syst Rev; 2021 Mar 23; 3(3):CD012862. PubMed ID: 33783815
    [Abstract] [Full Text] [Related]

  • 19. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C, Verhave JC, Berger SP, van de Kar NCAJ, Wetzels JFM.
    Am J Kidney Dis; 2017 Dec 23; 70(6):770-777. PubMed ID: 28821363
    [Abstract] [Full Text] [Related]

  • 20. Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials.
    Dixon BP, Kavanagh D, Aris ADM, Adams B, Kang HG, Wang E, Garlo K, Ogawa M, Amancha P, Chakravarty S, Heyne N, Kim SH, Cataland S, Yoon SS, Miyakawa Y, Luque Y, Muff-Luett M, Tanaka K, Greenbaum LA.
    Kidney Med; 2024 Aug 23; 6(8):100855. PubMed ID: 39105067
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.